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well as a combined cystatin C- and creatinine-based eGFR equation, in
predicting death in acute HF patients within six months after hospital
discharge. Additionally we intended to determine the added value of
cystatin C in risk stratiﬁcation in this population, compared to
creatinine-based eGFR alone.
We prospectively enrolled patients consecutively admitted with
acute HF, who were discharged alive, excluding those with acute
coronary syndromes or on chronic renal function replacement therapy.
Fasting venous blood sampleswere collected on discharge day.We used
four creatinine-based GFR estimating equations — Cockcroft–Gault,
Modiﬁcation of Diet in Renal Disease (MDRD-6), IDMS-traceableRenal function impairment is frequent in acute heart failure (HF)
episodes and is one of the most powerful determinants of outcome [1].
Glomerular ﬁltration rate (GFR) is a widely accepted measure of
renal function, and it may be estimated using several equations. The
most frequently used are based on serum creatinine, although they
are less accurate in over- and underweight patients, and in the extremes
of renal function, since they tend to overestimate lower ﬁltration rates
and underestimate more elevated ﬁltration rates [2]. Recent research
has moved the focus towards potentially better and more sensitive
markers of kidney function. Cystatin C has arisen as an interesting
alternative, and cystatin C-based equations estimating GFR have been
developed, and, when compared to creatinine and creatinine-based
equations, provide similarly or evenmore accuratemeasures of GFR [3].s from “Fundação para a Ciência
U-ESA/107940/2008].
ão, Alameda Professor Hernâni
.We aimed to assess the discrimination and predictive value of
creatinine- and cystatin C-based estimated GFR (eGFR) equations, as
simpliﬁed MDRD (MDRD-4) and CKD-EPI creatinine (CKD-EPICr) — ,
two cystatin C-based equations — from Rule et al. (CysCeq) [4] and
CKD-EPI cystatin C (CKD-EPICysC) [3]— and an equation using both cre-
atinine and cystatin C— CKD-EPI creatinine-cystatin C (CKD-EPICrCysC)
[3]. The endpoint was 6-month all-cause death.
We used Kaplan–Meier to estimate the risk of 6-month all-cause
death, according to the classes of eGFR for each equation, and Cox
regression to quantify the association between eGFR categories and
death. Net reclassiﬁcation improvement (NRI) assessed the incremental
value for predicting death when adding a cystatin C-based to a
creatinine-based equation to classify GFR. Statistical analyses were
performed using Stata 11.1 for Windows (StataCorp LP, College
Station, TX).
The study protocol conforms to the ethical principles outlined in the
Declaration of Helsinki, the local ethics committee approved the study,
and informed consent was obtained.
Of the 478 patients included in the analysis 47%weremen, themean
age was 75.6 years, and 41.9% had preserved ejection fraction. Mean
serum creatinine and serum cystatin C at hospital discharge were
1.53 mg/dL and 1.64 mg/L, respectively. Ninety patients (18.8%) died
during follow-up.
The distribution of patients across eGFR groups, according to the
equations, is presented in Table 1. Using Spearman's correlation and
Kappa coefﬁcient, we found that the estimates from creatinine-based
Table 1
Distribution of patients across GFR groups, and crude association and predictive value of classes of GFR, estimated according to different equations, for all-cause death within six months.
eGFR (mL/min/1.73 m2)
≥90 60–89 30–59 b30 p for trend
Cockcroft–Gault n (%) 18 (3.8) 66 (13.8) 255 (53.4) 139 (29.1) b0.001
6 m (%) 6.7 6.2 17.5 29.8
HR (95% CI) 1 1.13 (0.13–10.09) 3.41 (0.47–24.74) 6.24 (0.86–45.39)
MDRD-4 n (%) 16 (3.4) 85 (17.8) 281 (58.8) 96 (20.1) 0.057
6 m (%) 6.7 19.0 16.9 27.5
HR (95% CI) 1 3.37 (0.45–25.39) 2.96 (0.41–21.48) 4.94 (0.67–36.41)
MDRD-6 n (%) 27 (5.7) 126 (26.5) 242 (50.8) 81 (17.0) 0.001
6 m (%) 11.6 12.8 18.9 32.4
HR (95% CI) 1 1.21 (0.35–4.15) 1.83 (0.57–5.89) 3.36 (1.02–11.11)
CKD-EPICr n (%) 17 (3.6) 59 (12.3) 230 (48.1) 172 (36.0) 0.012
6 m (%) 6.3 15.3 16.3 25.3
HR (95% CI) 1 2.82 (0.36–22.28) 3.03 (0.42–22.09) 4.84 (0.67–35.14)
CysCeq n (%) 21 (4.4) 92 (19.3) 231 (48.3) 134 (28.0)
6 m (%) 0 10.2 16.3 33.0
HR (95% CI) 1 2.14 (1.03–4.44) 4.80 (2.34–9.83) b0.001
CKD-EPICysC n (%) 39 (8.2) 88 (18.4) 220 (46.0) 131 (27.4) b0.001
6 m (%) 7.8 10.5 16.2 33.0
HR (95% CI) 1 1.39 (0.38–5.14) 2.24 (0.69–7.28) 5.09 (1.58–16.42)
CKD-EPICrCysC n (%) 27 (5.7) 91 (19.0) 245 (51.3) 115 (24.1) b0.001
6 m (%) 4.0 13.4 17.8 29.8
HR (95% CI) 1 3.85 (0.50–29.62) 5.32 (0.73–38.62) 9.47 (1.30–69.18)
eGFR = estimated glomerular ﬁltration rate.
Cockcroft–Gault = Cockcroft–Gault equation.
MDRD-4 = simpliﬁed Modiﬁcation of Diet in Renal Disease equation.
MDRD-6 =Modiﬁcation of Diet in Renal Disease equation.
CKD-EPICr = Chronic Kidney Disease Epidemiology Collaboration creatinine equation.
CysCeq = cystatin C-based equation from Rule et al.
CKD-EPICysC = Chronic Kidney Disease Epidemiology Collaboration cystatin C equation.
CKD-EPICrCysC = Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation.
6 m = 6-month risk of all-cause death.
HR = Crude Hazard Ratio.
95% CI = 95% conﬁdence interval.
Fig. 1.Risk prediction for all-cause deathwithin sixmonths, based on the additive value of
Cockcroft–Gault and CKD-EPICysC estimates of glomerular ﬁltration rate.
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estimates from cystatin C-based equations. The two equations using
cystatin C were strongly correlated with each other and with the
combined equation (data not shown).
The risk of death increased progressively across categories of eGFR
for all equations (Table 1). Among the creatinine-based equations,
Cockcroft–Gault provided the largest increase in risk of death. Cystatin
C-based equations performed similarly, with a strong increase in risk
across categories of eGFR. The combined equation yielded the largest
increase in the predicted risk of death.
Given that cystatin C is less readily available, we assessed the added
value by subgroups of Cockcroft–Gault eGFR. Whereas for eGFR b 30
or ≥60 mL/min/1.73 m2 according to Cockcroft–Gault, cystatin C
or cystatin C-based eGFR did not discriminate prognosis further,
patients who had Cockcroft–Gault eGFR 30–59 mL/min/1.73 m2 were
reclassiﬁed by CKD-EPICysC equation into three subgroups of patients
with different outcomes (Fig. 1). The incremental prognostic predictive
ability of a cystatin C-based equation was further analysed by measur-
ing the NRI, compared to Cockcroft–Gault alone. The addition of CKD-
EPICysC in this group of patients showed a signiﬁcant improvement
in risk prediction for 6-month all-cause mortality over Cockcroft–
Gault: NRI = 46% (95% conﬁdence interval: 23 to 69, p b 0.001). CysCeq
yielded a NRI = 48% (95% conﬁdence interval: 25 to 71, p b 0.001).
The addition of the combined equation did not show a signiﬁcant
improvement in risk prediction ability.
The prognostic value of eGFR calculated by different equations in HF
patients has been previously assessed, with ﬁndings of superior
accuracy of CKD-EPICr over MDRD-4 [5]. These equations have also
been compared with Cockcroft–Gault in chronic HF [6], and the latter
revealed to be the best estimator of renal function for the prediction of
long-term mortality, the same as in our work.
When compared to creatinine and creatinine-based eGFR equations,
cystatin C is a similarly good marker of prognosis stratiﬁcation in HFpatients, particularly in those with moderate renal dysfunction [7]. A
better prognostic value of cystatin C-based over creatinine-based
equations has been observed in diverse populations. In a recent meta-
analysis of 11 general population studies and 5 cohorts with chronic
kidney disease, the use of eGFR based on cystatin C alone or in combina-
tion with creatinine, strengthened the association between the eGFR
and the risks of death and end-stage renal disease [8]. In chronic HF,
cystatin C-based also showed superior prognostic accuracy over
creatinine-only based equations, particularly in patients with moderate
renal dysfunction [9]. The utility of these equations in prognosis
72 M. Alvelos et al. / International Journal of Cardiology 196 (2015) 70–72stratiﬁcation of acuteHF patients only recently has been addressed [10],
and CKD-EPICysC and CKD-EPICrCysC were both superior to MDRD-4
for predicting long-term mortality and/or HF hospitalisation. However,
contrarily to our ﬁndings, the better prognostic power of cystatin
C-based equations was seen in patients with eGFR ≥ 60 mL/min/
1.73 m2. These apparently conﬂicting results may be related to the fact
that the creatinine-based equation used was MDRD-4, an equation
that has better performance in patients with lower ﬁltration rates.
Creatinine-based estimates of GFRwill continue to be used in clinical
practice, particularly given its low cost and universal availability.
Nevertheless, we demonstrated that cystatin C-based estimation of
GFR can reﬁne the prognostic exercise of clinicians in acute HF patients
with moderate renal dysfunction at hospital discharge.
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